English  |  正體中文  |  简体中文  |  Total items :2817692  
Visitors :  27834716    Online Users :  530
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

Jump to a point in the index:
Or type in a year:
Show Most Recent First Ordering With Oldest First

Showing items 2265026-2265035 of 2309225  (230923 Page(s) Totally)
<< < 226498 226499 226500 226501 226502 226503 226504 226505 226506 226507 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-06-10T06:10:55Z Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; ZHONG-ZHE LIN; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏 2022-06-10T06:10:55Z A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy ZHONG-ZHE LIN; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏 2022-06-10T06:10:56Z Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN; Cheng A.-L.; Hsu C.-H.
臺大學術典藏 2022-06-10T06:10:56Z First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.
臺大學術典藏 2022-06-10T06:10:57Z Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status Chen H.-C.; Tan E.C.-H.; Liao C.-H.; ZHONG-ZHE LIN; Yang M.-C.
臺大學術典藏 2022-06-10T06:10:57Z Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; ZHONG-ZHE LIN; Lin C.-C.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2022-06-10T06:10:57Z Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma ZHONG-ZHE LIN; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:10:58Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2022-06-10T06:10:58Z Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; ZHONG-ZHE LIN; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2022-06-10T06:10:59Z A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.

Showing items 2265026-2265035 of 2309225  (230923 Page(s) Totally)
<< < 226498 226499 226500 226501 226502 226503 226504 226505 226506 226507 > >>
View [10|25|50] records per page